Testosterone 5-alpha-reductase: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In biology, '''testosterone 5-alpha-reductase''' is an enzyme that produced dihydrotestosterone. Inhibitors are finasteride and dutasteride are used to treat [[benign prostati...) |
imported>Robert Badgett No edit summary |
||
| Line 2: | Line 2: | ||
Inhibitors are [[finasteride]] and [[dutasteride]] are used to treat [[benign prostatic hypertrophy]]. Both of these medications are metaoblized by [[cytochrome P-450 CYP3A4]]. | Inhibitors are [[finasteride]] and [[dutasteride]] are used to treat [[benign prostatic hypertrophy]]. Both of these medications are metaoblized by [[cytochrome P-450 CYP3A4]]. | ||
Dutasteride may better prevent acute urinary retention rates than finasteride effective according to a [[cohort study]].<ref name="pmid18611089">{{cite journal| author=Fenter TC, Davis EA, Shah MB, Lin PJ| title=Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. | journal=Am J Manag Care | year= 2008 | volume= 14 | issue= 5 Suppl 2 | pages= S154-9 | pmid=18611089 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=18611089 }} </ref> may better lower dihydrotestosterone.<ref name="pmid15126539">{{cite journal| author=Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S| title=Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. | journal=J Clin Endocrinol Metab | year= 2004 | volume= 89 | issue= 5 | pages= 2179-84 | pmid=15126539 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=15126539 }} </ref> It may also better reduce symptoms in preliminary trial.<ref name="pmid17364459">{{cite journal| author=Ravish IR, Nerli RB, Amarkhed SS| title=Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate. | journal=Arch Androl | year= 2007 Jan-Feb | volume= 53 | issue= 1 | pages= 17-20 | pmid=17364459 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=17364459 | doi=10.1080/01485010600888953 }} </ref> | |||
<references/> | |||
Revision as of 12:33, 12 April 2010
In biology, testosterone 5-alpha-reductase is an enzyme that produced dihydrotestosterone.
Inhibitors are finasteride and dutasteride are used to treat benign prostatic hypertrophy. Both of these medications are metaoblized by cytochrome P-450 CYP3A4.
Dutasteride may better prevent acute urinary retention rates than finasteride effective according to a cohort study.[1] may better lower dihydrotestosterone.[2] It may also better reduce symptoms in preliminary trial.[3]
- ↑ Fenter TC, Davis EA, Shah MB, Lin PJ (2008). "Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.". Am J Manag Care 14 (5 Suppl 2): S154-9. PMID 18611089.
- ↑ Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S (2004). "Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.". J Clin Endocrinol Metab 89 (5): 2179-84. PMID 15126539.
- ↑ Ravish IR, Nerli RB, Amarkhed SS (2007 Jan-Feb). "Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.". Arch Androl 53 (1): 17-20. DOI:10.1080/01485010600888953. PMID 17364459. Research Blogging.